Workflow
Longeveron(LGVN)
icon
Search documents
Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)
Newsfilter· 2024-04-15 12:30
MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the Company's CLEAR MIND Phase 2a study results. CLEAR-MIND is a Phase 2a randomized clinical trial evaluating Lomecel-BTM in mild Alzheimer's Disease. In addition to the clinical study results, the Company has been accepted for a poster presentation at the 2024 Alzheim ...
Longeveron(LGVN) - 2023 Q4 - Earnings Call Transcript
2024-02-28 02:56
Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Conference Call February 27, 2024 5:00 PM ET Company Participants Mike Moyer – Managing Director Wa'el Hashad – Chie Executive Officer Nataliya Agafonova – Chief Medical Officer Lisa Locklear – Chief Financial Officer Conference Call Participants Dipesh Patel – H.C. Wainwright Michael Okunewitch – Maxim Group Brad Sorensen – Zacks Research Operator Ladies and gentlemen, good afternoon, and welcome to the Longeveron Fourth Quarter and Full Year 2023 Earnings Con ...
Longeveron(LGVN) - 2023 Q4 - Annual Report
2024-02-27 21:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40060 LONGEVERON INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organi ...
Longeveron(LGVN) - 2023 Q3 - Earnings Call Transcript
2023-11-10 15:27
Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Conference Call November 10, 2023 8:30 AM ET Company Participants Mike Moyer - Managing Director, LifeSci Advisors, LLC Wa’el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Joshua M. Hare - Co-Founder, Chief Science Officer and Chairman Conference Call Participants Michael Okunewitch - Maxim Group Operator Greetings, and welcome to the Longeveron’s Third Quarter 2023 Earnings call. At this time, all participants are in a listen-only mode. A brief que ...
Longeveron(LGVN) - 2023 Q3 - Earnings Call Presentation
2023-11-10 13:17
ASRM approval can lead to revenue generation years before BLA application with FDA or conditional approval by PMDA Clinical Trial in Japan (N=45) ‒ NCGG (Nagoya) and Juntendo University (Tokyo) selected as clinical sites *Frailty/Aging-Related Frailty" presently does not have a consensus definition of the indication for regulatory purposes; however, it is likely that safety as observed in the proposed Phase 2 trial in Japan combined with the US Frailty 2b study will result in ASRM approval • Previous therap ...
Longeveron(LGVN) - 2023 Q3 - Quarterly Report
2023-11-09 21:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40060 Longeveron Inc. (Exact name of registrant as specified in its charter) | Delaware | 47-2174146 | | --- | --- | | (State or Other ...
Longeveron(LGVN) - 2023 Q2 - Quarterly Report
2023-08-11 12:58
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40060 Longeveron Inc. (Exact name of registrant as specified in its charter) Delaware 47-2174146 (State or Other Jurisdiction of Incorporat ...
Longeveron(LGVN) - 2023 Q1 - Quarterly Report
2023-05-12 20:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40060 Longeveron Inc. (Exact name of registrant as specified in its charter) Delaware 47-2174146 (State or Other Jurisdiction of Incorpo ...
Longeveron(LGVN) - 2023 Q1 - Earnings Call Transcript
2023-05-12 18:14
Longeveron Inc. (NASDAQ:LGVN) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants James Clavijo - Chief Financial Officer Wa'el Hashad - Chief Executive Officer Chris Min - Acting Chief Medical Officer & Consultant Conference Call Participants Michael Okunewitch - Maxim Group Operator Good morning, and welcome to Longeveron's call today to discuss the company's 2023 First Quarter and Financial Results. All participants are currently in listen-only mode. Following the formal present ...
Longeveron(LGVN) - 2022 Q4 - Annual Report
2023-03-14 21:22
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40060 LONGEVERON INC. (Exact name of registrant as specified in its charter) | Delaware | 47-2174146 | | --- | --- | | (State or Oth ...